FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a medicinal agent designated for treatment of inflammatory of obstructive disease of respiratory way and represents the combination of two components. Component (A) represents formoterol or its pharmaceutically acceptable salt or solvate of formoterol or indicated salt. Component (B) represents thiotropium salt and pharmaceutically acceptable acid. The mass ratio of component (A) to component (B) = from (72:1) to (1:160). Agent is designated for simultaneous, sequential or separate administration of indicated components. Agent provides synergetic therapeutic effect and results to rapid effect and prolonged effect with minimal adverse effect.
EFFECT: valuable medicinal properties of compositions.
12 cl, 256 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL AGENT AND PHARMACEUTICAL SET DESIGNATED FOR ASTHMA TREATMENT | 2000 |
|
RU2270670C2 |
| COMPOSITIONS INCLUDING FORMOTEROL AND FLUCTICASON PROPIONATE INDICATED FOR TREATING ASTHMA | 2000 |
|
RU2249454C2 |
| PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2568882C2 |
| COMBINATIONS CONTAINING ANTI-MUSCARINE PREPARATIONS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2379033C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2642624C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2404771C2 |
| COMBINATION AND PHARMACEUTICAL PREPARATION FOR TREATING INFLAMMATORY AND OBSTRUCTIVE RESPIRATORY DISEASES | 2005 |
|
RU2438660C2 |
| INHALATION PARTICLES CONTAINING COMBINATION OF ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENTS | 2015 |
|
RU2697867C2 |
| APPLICATION OF TIOTROPIUM SALTS FOR TREATMENT OF SEVERE FORMS OF PERSISTENT ASTHMA | 2006 |
|
RU2422144C2 |
| NEW DOSE AND FORMULATION | 2009 |
|
RU2608713C2 |
